Dutch researchers used radiolabeling to observe certolizumab in the body for the first time. Such studies could provide a greater understanding of how TNF inhibitors can be best used in the treatment of inflammatory conditions like arthritis.
There are five different tumor necrosis factor (TNF) inhibitors available for the treatment of RA. Researchers say that despite showing similar efficacy, they differ in molecular structures and signaling disruption.
The FDA this week announced approval of Maci, “matrix-induced autologous chondrocyte implantation.” The treatment is intended for cartilage defects of the knee, which can eventually lead to osteoarthritis.